Citius Pharmaceuticals (NASDAQ:CTXR) reported quarterly losses of $(0.02) per share. This is a 66.67 percent increase over losses of $(0.06) per share from the same period last year.
Why Sonnet BioTherapeutics (SONN) Stock Is Getting Hammered
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company announced the pricing of a public offering involving 2,843,750 shares of common stock or pre-funded warrants, along with investor warrants allowing the purchase
